Seeking optimization of LT4 treatment in patients with differentiated thyroid cancer

Levothyroxine sodium (LT4) is the mainstay treatment to replace thyroid hormonal production in thyroidectomized patients, but, depending on the aggressiveness of the cancer and on the risk of recurrence, patients with differentiated thyroid cancer may also be treated in a TSH-suppressive or semi-sup...

Descripción completa

Detalles Bibliográficos
Autores principales: Stramazzo, Ilaria, Capriello, Silvia, Antonelli, Alessandro, Fallahi, Poupak, Centanni, Marco, Virili, Camilla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712340/
https://www.ncbi.nlm.nih.gov/pubmed/35655116
http://dx.doi.org/10.1007/s42000-022-00376-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712340/
https://www.ncbi.nlm.nih.gov/pubmed/35655116
http://dx.doi.org/10.1007/s42000-022-00376-9

Ejemplares similares